Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2024

18.03.2023 | Maternal-Fetal Medicine

Do small for gestational age fetuses have placental pathologies?

verfasst von: Pinar Calis, Ayse Cakir Gundogdu, Ezgi Turgut, Cemile Merve Seymen, Atiye Seda Saglam, Deniz Karcaaltincaba, Gulnur Take Kaplanoglu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although small for gestational age (SGA) does not cause adverse perinatal outcomes, the placental pathology for fetal growth restricted (FGR) and SGA fetuses is still unknown. The aim of this study is to evaluate the differences between placentas of early onset FGR, late onset FGR, SGA, and appropriate for gestational age (AGA) pregnancies in the manner of microvasculature and expression of anti-angiogenic PEDF factor and CD68.

Methods

The study included four groups (early onset FGR, late onset FGR, SGA and AGA). Placental samples were obtained just after labor in all of the groups. Degenerative criteria were investigated with Hematoxylin–eosin staining. Immunohistochemical evaluation with H score and m RNA levels of Cluster of differentiation 68 (CD68) and pigment epithelium derived factor (PEDF) were performed for each group.

Results

The highest levels of degeneration were detected in the early onset FGR group. In means of degeneration SGA placentas were found to be worse than the AGA placentas. The intensity of PEDF and CD68 were significant in early FGR, the late FGR and SGA groups compared to the AGA group (p < 0.001). The mRNA level results of the PEDF and CD68 were also parallel to the immunostaining results.

Conclusion

Although SGA fetuses are considered constitutionally small, the SGA placentas also demonstrated signs of degeneration similar to the FGR placentas. These degenerative signs were not seen among the AGA placentas.
Literatur
1.
Zurück zum Zitat Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marcal VM et al (2017) Fetal growth restriction: current knowledge. Arch Gynecol Obstet 295(5):1061–1077CrossRefPubMed Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marcal VM et al (2017) Fetal growth restriction: current knowledge. Arch Gynecol Obstet 295(5):1061–1077CrossRefPubMed
2.
Zurück zum Zitat Froen JF, Gardosi JO, Thurmann A, Francis A, Stray-Pedersen B (2004) Restricted fetal growth in sudden intrauterine unexplained death. Acta Obstet Gynecol Scand 83(9):801–807CrossRefPubMed Froen JF, Gardosi JO, Thurmann A, Francis A, Stray-Pedersen B (2004) Restricted fetal growth in sudden intrauterine unexplained death. Acta Obstet Gynecol Scand 83(9):801–807CrossRefPubMed
3.
Zurück zum Zitat Fetal Growth Restriction (2021) ACOG Practice Bulletin, Number 227. Obstet Gynecol 137(2):e16–e28CrossRef Fetal Growth Restriction (2021) ACOG Practice Bulletin, Number 227. Obstet Gynecol 137(2):e16–e28CrossRef
4.
Zurück zum Zitat Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN et al (2016) Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 48(3):333–339CrossRefPubMed Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN et al (2016) Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 48(3):333–339CrossRefPubMed
5.
Zurück zum Zitat Molina LCG, Odibo L, Zientara S, Obican SG, Rodriguez A, Stout M et al (2020) Validation of Delphi procedure consensus criteria for defining fetal growth restriction. Ultrasound Obstet Gynecol 56(1):61–66CrossRefPubMed Molina LCG, Odibo L, Zientara S, Obican SG, Rodriguez A, Stout M et al (2020) Validation of Delphi procedure consensus criteria for defining fetal growth restriction. Ultrasound Obstet Gynecol 56(1):61–66CrossRefPubMed
6.
Zurück zum Zitat Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD (2006) Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 113(5):580–589CrossRefPubMed Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD (2006) Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 113(5):580–589CrossRefPubMed
7.
Zurück zum Zitat Alahakoon TI, Zhang W, Arbuckle S, Zhang K, Lee V (2018) Reduced angiogenic factor expression in intrauterine fetal growth restriction using semiquantitative immunohistochemistry and digital image analysis. J Obstet Gynaecol Res 44(5):861–872CrossRefPubMed Alahakoon TI, Zhang W, Arbuckle S, Zhang K, Lee V (2018) Reduced angiogenic factor expression in intrauterine fetal growth restriction using semiquantitative immunohistochemistry and digital image analysis. J Obstet Gynaecol Res 44(5):861–872CrossRefPubMed
8.
Zurück zum Zitat Umapathy A, Chamley LW, James JL (2020) Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis 23(2):105–117CrossRefPubMed Umapathy A, Chamley LW, James JL (2020) Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis 23(2):105–117CrossRefPubMed
9.
Zurück zum Zitat Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M (1996) A United States national reference for fetal growth. Obstet Gynecol 87(2):163–168CrossRefPubMed Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M (1996) A United States national reference for fetal growth. Obstet Gynecol 87(2):163–168CrossRefPubMed
10.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408CrossRefPubMed Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408CrossRefPubMed
11.
Zurück zum Zitat Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30(9):e36CrossRefPubMedPubMedCentral Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30(9):e36CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Severi FM, Rizzo G, Bocchi C, D’Antona D, Verzuri MS, Arduini D (2000) Intrauterine growth retardation and fetal cardiac function. Fetal Diagn Ther 15(1):8–19CrossRefPubMed Severi FM, Rizzo G, Bocchi C, D’Antona D, Verzuri MS, Arduini D (2000) Intrauterine growth retardation and fetal cardiac function. Fetal Diagn Ther 15(1):8–19CrossRefPubMed
13.
Zurück zum Zitat Spinillo A, Gardella B, Adamo L, Muscettola G, Fiandrino G, Cesari S (2019) Pathologic placental lesions in early and late fetal growth restriction. Acta Obstet Gynecol Scand 98(12):1585–1594CrossRefPubMed Spinillo A, Gardella B, Adamo L, Muscettola G, Fiandrino G, Cesari S (2019) Pathologic placental lesions in early and late fetal growth restriction. Acta Obstet Gynecol Scand 98(12):1585–1594CrossRefPubMed
14.
Zurück zum Zitat Junaid TO, Brownbill P, Chalmers N, Johnstone ED, Aplin JD (2014) Fetoplacental vascular alterations associated with fetal growth restriction. Placenta 35(10):808–815CrossRefPubMed Junaid TO, Brownbill P, Chalmers N, Johnstone ED, Aplin JD (2014) Fetoplacental vascular alterations associated with fetal growth restriction. Placenta 35(10):808–815CrossRefPubMed
15.
Zurück zum Zitat Wu Y, Chen X, Jiao S, Wang Y (2021) Upregulated pigment epithelium-derived factor (PEDF) promotes trophoblast apoptosis and inhibits invasion in preeclampsia. Reprod Biol 21(4):100576CrossRefPubMed Wu Y, Chen X, Jiao S, Wang Y (2021) Upregulated pigment epithelium-derived factor (PEDF) promotes trophoblast apoptosis and inhibits invasion in preeclampsia. Reprod Biol 21(4):100576CrossRefPubMed
Metadaten
Titel
Do small for gestational age fetuses have placental pathologies?
verfasst von
Pinar Calis
Ayse Cakir Gundogdu
Ezgi Turgut
Cemile Merve Seymen
Atiye Seda Saglam
Deniz Karcaaltincaba
Gulnur Take Kaplanoglu
Publikationsdatum
18.03.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-023-06989-8

Weitere Artikel der Ausgabe 4/2024

Archives of Gynecology and Obstetrics 4/2024 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.